Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.

JCI insight - 8 Jun 2026

Specht Emma, Pakanati Lakshmi, Wu Meng-Ju, Jenkins Russell W, Effiom Derek N, Bardeesy Nabeel, Bernstein Bradley E, Sade-Feldman Moshe, Lian Christine G, Boland Genevieve M, Torlai Triglia Elena, Cohen Sonia

Abstract excerpt

Recent innovations in melanoma treatment with immune checkpoint blockade (ICB) have improved overall outcomes for patients; however, over 50% of patients still develop resistance to treatment. These patients either have intrinsic resistance and never respond to therapy or develop acquired resistance months or years into treatment. The mechanisms underlying ICB resistance remain poorly understood. Our data show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Methylation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Isocitrate Dehydrogenase

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41955022
DOI: 10.1172/jci.insight.195384
PMCID: PMC13313554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.PMID 41955022Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanomaSemantic proximity Read ↗

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Semantic proximity Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.Semantic proximity Read ↗

Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanomaSemantic proximity Read ↗

Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanomaSemantic proximity Read ↗

Specific Aneuploidies Predict Immune Evasion and Poor Immunotherapy Response in MelanomaSemantic proximity Read ↗

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Semantic proximity Read ↗

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade ResponseSemantic proximity Read ↗

Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.